<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Geriatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Geriatr</journal-id><journal-title-group><journal-title>BMC Geriatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2318</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12102864</article-id><article-id pub-id-type="publisher-id">6004</article-id><article-id pub-id-type="doi">10.1186/s12877-025-06004-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>My patient might be depressed &#x02013; can I still screen for MCI? Exploring cognitive performance on the MoCA in older people screened for depressive symptoms with the PHQ-9</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0008-6268-2568</contrib-id><name><surname>B&#x000f6;sl</surname><given-names>Sophia</given-names></name><address><email>sophia.boesl@uk-erlangen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7794-1165</contrib-id><name><surname>Scheerbaum</surname><given-names>Petra</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Graessel</surname><given-names>Elmar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7794-8375</contrib-id><name><surname>Kessler</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5764-346X</contrib-id><name><surname>Scheuermann</surname><given-names>Julia-Sophia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f7hpc57</institution-id><institution-id institution-id-type="GRID">grid.5330.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 3311</institution-id><institution>Centre for Health Services Research in Medicine, Department of Psychiatry and Psychotherapy, </institution><institution>Uniklinikum Erlangen, Friedrich-Alexander-Universit&#x000e4;t Erlangen-N&#x000fc;rnberg (FAU), </institution></institution-wrap>Schwabachanlage 6, D-91054 Erlangen, Germany </aff><aff id="Aff2"><label>2</label>Department of Internal and Nature-Based Therapies, Immanuel Hospital Berlin, D-14109 Berlin, Germany </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>374</elocation-id><history><date date-type="received"><day>26</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">The aim of this study was to compare the Montreal Cognitive Assessment (MoCA) performances of people who report no, subclinical, and clinical symptoms of depression.</p></sec><sec><title>Methods</title><p id="Par2">Data was collected for the randomized controlled trial BrainFit-Nutrition. A secondary data analysis of 1,111 participants (age&#x02009;&#x02265;&#x02009;60 years; <italic>M</italic>&#x02009;=&#x02009;68.4 years; 55.1% female) was performed. Depressive symptoms were assessed with the Patient Health Questionnaire-9 (PHQ-9), cognitive performance was assessed via the MoCA. Performance differences were tested with Kruskal-Wallis tests. Two sensitivity analyses were conducted, one with data from people with MCI and one with the original item structure of the MoCA.</p></sec><sec><title>Results</title><p id="Par3">No differences were found in the MoCA total score or in visuospatial, executive functioning, attention, memory, or orientation subscores between individuals with no, subclinical, or clinical symptoms of depression. A sensitivity analysis also showed no differences.</p></sec><sec><title>Conclusion</title><p id="Par4">Cognitive screening with the MoCA seems to be robust against depression and could therefore be used to screen for MCI regardless of depression level.</p></sec><sec><title>Trial registration</title><p id="Par5">The study was prospectively registered at the International Standard Randomized Controlled Trial Number Registry on 23/11/2021 (ISRCTN 10560738).</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12877-025-06004-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>MoCA</kwd><kwd>Depressive symptoms</kwd><kwd>Cognitive performance</kwd><kwd>Older people</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#x000e4;tsklinikum Erlangen (8546)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">The Montreal Cognitive Assessment (MoCA) [<xref ref-type="bibr" rid="CR1">1</xref>] is used globally to screen for Mild Cognitive Impairment (MCI), as it has high sensitivity and specificity and can be administered easily and quickly [<xref ref-type="bibr" rid="CR2">2</xref>]. Detection of MCI is essential for early treatment [<xref ref-type="bibr" rid="CR3">3</xref>], as MCI is a prodromal stage to dementia [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] and describes the decline in a person&#x02019;s cognitive functioning as they transition from normal aging to dementia [<xref ref-type="bibr" rid="CR6">6</xref>]. Thus, people with MCI are at significantly higher risk of developing dementia than cognitively healthy people [<xref ref-type="bibr" rid="CR4">4</xref>]. However, it seems that not only MCI but also affective disorders, e.g. depression, have an impact on participants&#x02019; cognitive performance on the MoCA, at least in a clinical setting [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par7">Depression is a mental disorder affecting over 300&#x000a0;million people of all ages worldwide [<xref ref-type="bibr" rid="CR8">8</xref>]. In the older population (people 60 years of age and older), the prevalence is estimated to range from 17.5 to 31.7% [<xref ref-type="bibr" rid="CR9">9</xref>]. Amongst other symptoms, impaired cognitive functioning, e.g. memory difficulties or limited concentration, can be present in people with depressive disorders [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, the distinction between depressive symptoms and early signs of dementia is complex, especially for older people [<xref ref-type="bibr" rid="CR11">11</xref>], but it is clinically important. Depressive symptoms are assumed to be a risk factor for dementia [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>] and can also emerge during the prodromal stage of dementia [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par8">Regarding specific dimensions of cognitive functioning, lower performance has been reported in memory [<xref ref-type="bibr" rid="CR16">16</xref>], language [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>], and executive as well as visuospatial functioning [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>] in older people with depression compared with non-depressed controls. People with MCI and depression seem to perform worse on items that measure visuospatial, memory, and executive functioning [<xref ref-type="bibr" rid="CR21">21</xref>] compared with people with MCI without depression. Additionally, global cognitive functioning as well as memory, semantic fluency, and processing speed seem to decline more quickly in people with MCI and chronic subsyndromal, i.e. subclinical, depressive symptoms compared with people with MCI and no depressive symptoms [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par9">In order to avoid false positive results in screened patients, it is necessary to know whether there are differences in the MoCA performance of older people with and without symptoms of depression so that the results can be interpreted accordingly. However, no information about potential differences in performance is available for the German version of the MoCA. It is therefore necessary to investigate whether differences in performance, as assessed with the total score and subscores from the German version of the MoCA, can be observed in people with and without depressive symptoms.</p><p id="Par10">On the basis of previous research [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], we hypothesized that MoCA subscores for memory, language, executive functioning, and visuospatial functioning as well as the total score would differ across older people with symptoms of clinical depression, symptoms of subclinical depression, and no depressive symptoms.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Design and sample</title><p id="Par11">The secondary analysis was based on the screening data from the randomized controlled trial BrainFit-Nutrition. The study design was previously published as a study protocol [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par12">More than 1,100 people across Germany aged 60 and older were screened for MCI between January and September of 2022. For the following analysis, data from all participants who completed the first part of the screening were used (<italic>N</italic>&#x02009;=&#x02009;1,111), thus avoiding a selection bias. In order to enable all residents of Germany to participate, the study was conducted completely remotely. The screening was performed as a video conference using the remote software samedi &#x02013; certified from the German National Association of Statutory Health Insurance Physicians [<xref ref-type="bibr" rid="CR24">24</xref>]. During the video conference, the interviewer entered the participants&#x02019; answers into the data collection system REDCap. If data entries were missing or invalid, the interviewer was immediately asked to correct the entry. In the screening for BrainFit-Nutrition study participation, the following information was assessed: completely blind or deaf; diagnosis of pre-existing somatic or psychiatric conditions that can cause cognitive impairment, e.g. psychosis, multiple sclerosis, Parkinson&#x02019;s disease, or multiple strokes; symptoms of depression, assessed with the Patient Health Questionnaire-9 (PHQ-9) [<xref ref-type="bibr" rid="CR25">25</xref>]; the presence of MCI, defined as a MoCA score&#x02009;&#x0003e;&#x02009;24 [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. Screening procedure for the study was terminated if participants met at least one of the exclusion criteria described in detail in the study protocol [<xref ref-type="bibr" rid="CR23">23</xref>]. In Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, screening procedure is described and information of the participants used for the present analysis is shown. All procedures were approved by the Ethics Committee of the medical faculty of the Friedrich-Alexander-Universit&#x000e4;t Erlangen-N&#x000fc;rnberg (Ref.: 21&#x02013;318_1-B). The study was prospectively registered at the International Standard Randomized Controlled Trial Number Registry on 23/11/2021 (ISRCTN 10560738).</p><p id="Par13">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Screening procedure for BrainFit-Nutrition</p><p>Note. PHQ-9, Patient Health Questionnaire-9, range 0&#x02013;27; MMSE, Mini Mental Status Examination, range 0&#x02013;30; MoCA, Montreal Cognitive Assessment, range 0&#x02013;30. All information used for the present analysis is marked in grey</p></caption><graphic xlink:href="12877_2025_6004_Fig1_HTML" id="d33e352"/></fig>
</p></sec><sec id="Sec4"><title>Instruments</title><sec id="Sec5"><title>PHQ-9</title><p id="Par14">The PHQ-9 is a short questionnaire with nine items concerning different depressive symptoms within the last two weeks [<xref ref-type="bibr" rid="CR25">25</xref>]. Each item can be answered on a scale ranging from 0 (&#x0201c;not at all&#x0201c;) to 3 (&#x0201c;nearly every day&#x0201c;), resulting in a maximum possible total score of 27. Originally, to determine the severity of the depressive episode, several cut-offs were established [<xref ref-type="bibr" rid="CR25">25</xref>]: minimal (0&#x02013;4), mild (5&#x02013;9), moderate (10&#x02013;14), moderately severe (15&#x02013;19), and severe (20&#x02013;27). However, a cut-off of &#x02265;&#x02009;10 was found to have the highest sensitivity and specificity in distinguishing between people with and without symptoms of a major depressive episode [<xref ref-type="bibr" rid="CR29">29</xref>]. As cognitive impairments may already occur in individuals with a subsyndromal depressive episode [<xref ref-type="bibr" rid="CR22">22</xref>], in accordance with Kroenke et al. [<xref ref-type="bibr" rid="CR25">25</xref>] we set the following cut-offs for depressive symptoms in the present study: &#x0201c;no&#x02013; minimal&#x0201d; (0&#x02013;4), &#x0201c;subclinical&#x0201d; (5&#x02013;9), and &#x0201c;clinical&#x0201d; (&#x02265;&#x02009;10) symptoms of depression.</p></sec><sec id="Sec6"><title>MoCA</title><p id="Par15">The MoCA is a screening tool with high sensitivity and specificity [<xref ref-type="bibr" rid="CR1">1</xref>], which can be used to differentiate between individuals with and without MCI. The instrument covers multiple cognitive domains, namely, visuospatial and executive functioning, speech, attention, memory, and orientation [<xref ref-type="bibr" rid="CR1">1</xref>]. The items comprising each subscore can be found in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. A total score of 30 can be achieved, and a score of &#x02264;&#x02009;24 indicates MCI [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. It is unclear whether verbal fluency is part of the executive or the language subscore [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In Nasreddine et al. [<xref ref-type="bibr" rid="CR1">1</xref>], verbal fluency was assigned to both subscores. However, the task for verbal fluency in the MoCA is more of an assessment of phonemic fluency and can therefore be assigned to the executive subscore, in contrast to semantic fluency [<xref ref-type="bibr" rid="CR32">32</xref>]. For the current analysis, the decision was therefore made to assign the verbal fluency task to the executive subdomain.</p><p id="Par16">The MoCA can be administered face-to-face or remotely. In the present study, the German adaption of the MoCA Version 8.1 was conducted remotely, based on the audio-visual conference protocol provided by the MoCA Clinic [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par17">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Components of the MoCA subscores</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Subscores<sup>a</sup></th><th align="left">Items</th><th align="left">Range</th></tr></thead><tbody><tr><td align="left">Visuospatial</td><td align="left">Clock-drawing test, cube-drawing test</td><td align="left">0&#x02013;4</td></tr><tr><td align="left">Executive</td><td align="left">Trail-making test, verbal fluency, verbal abstraction</td><td align="left">0&#x02013;4</td></tr><tr><td align="left">Attention</td><td align="left">Target detection task, serial subtraction task, digits forward and backward</td><td align="left">0&#x02013;6</td></tr><tr><td align="left">Memory</td><td align="left">Delayed recall task</td><td align="left">0&#x02013;5</td></tr><tr><td align="left">Language</td><td align="left">Confrontation naming task, repetition of sentences</td><td align="left">0&#x02013;5</td></tr><tr><td align="left">Orientation</td><td align="left">Questions about time and place</td><td align="left">0&#x02013;6</td></tr></tbody></table><table-wrap-foot><p><sup><italic>a</italic></sup>Adapted from Nasreddine et al., 2005 [<xref ref-type="bibr" rid="CR1">1</xref>]</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par18">In order to examine group differences in MoCA subscores, a multivariate analysis of variance (MANOVA) was chosen and assumptions were tested. Outliers were found, but these values had to be kept in the data set, as no errors in recording could be assumed. Normal distributions could not be achieved for any of the dependent variables after the data were transformed by inversion (Shapiro-Wilks test &#x003b1;&#x02009;&#x0003c;&#x02009;0.05). Further analyses were performed on the transformed data, and no multicollinearity between dependent variables was found (<italic>r</italic>&#x02009;&#x0003c;.80 in accordance with Field [<xref ref-type="bibr" rid="CR34">34</xref>]). Additionally, no multivariate outliers were found (assessed by Mahalanobis distance, <italic>p</italic>&#x02009;&#x0003e;.001). Homogeneity of error variances could be reported for the executive, attention, memory, and orientation subscores (<italic>p</italic>&#x02009;&#x0003e;.05) but not for the visuospatial (<italic>p</italic>&#x02009;=.010) or speech (<italic>p</italic>&#x02009;&#x0003c;.001) subscores. There was homogeneity of covariances (Box&#x02019;s test, <italic>p</italic>&#x02009;&#x0003e;.001).</p><p id="Par19">As several assumptions for the MANOVA were not met, a considerably reduced validity of its results must be assumed. Thus, the non-parametric multivariate Kruskal-Wallis test was conducted on the untransformed data to test for group differences (&#x003b1;&#x02009;=&#x02009;0.05).</p><p id="Par20">Due to different approaches of item categorization and different sample characteristics in the abovementioned studies, sensitivity analyses were performed for better comparisons. Therefore, a multivariate Kruskal-Wallis test was conducted using only the data from people with MCI (<italic>n</italic>&#x02009;=&#x02009;333) for better comparability with Lee et al. [<xref ref-type="bibr" rid="CR21">21</xref>]. Additionally, for another sensitivity analysis, the Kruskal-Wallis test was performed with the original item structure of the MoCA, removing the previously applied categorizations (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), as seen in Dierckx et al. [<xref ref-type="bibr" rid="CR20">20</xref>] and Blair et al. [<xref ref-type="bibr" rid="CR17">17</xref>]. All statistical analyses were carried out using IBM SPSS Statistics 28.0.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec83"><title>Main analysis</title><p id="Par21">Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> presents descriptive statistics for age, sex, and cognitive functioning for the overall sample as well as grouped by the PHQ-9 categories. Most of the participants (94.7%) did not report pre-existing somatic or psychiatric conditions that could cause cognitive decline; 4.8% reported one pre-existing condition, and 0.5% reported two. The sample&#x02019;s mean PHQ-9 score was 4.21 (<italic>SD</italic>&#x02009;=&#x02009;3.84) with 63.2% of the participants reporting no symptoms of depression, 26.1% reporting subclinical symptoms, and 10.7% reporting clinical symptoms. The mean MoCA score was 25.03 (<italic>SD</italic>&#x02009;=&#x02009;2.73). MCI, defined as MoCA&#x02009;&#x02264;&#x02009;24 was found in 34.5% of the total sample (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The MoCA total score and each MoCA subscore for both the total sample and all three depression categories can be found in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.</p><p id="Par22">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Descriptive statistics for the sample</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Total Sample<break/>(<italic>N</italic>&#x02009;=&#x02009;1,111)</th><th align="left" colspan="2">No Symptoms<break/>PHQ-9&#x02009;=&#x02009;0&#x02013;4<break/>(<italic>n</italic>&#x02009;=&#x02009;702)</th><th align="left" colspan="2">Subclinical Symptoms<break/>PHQ-9&#x02009;=&#x02009;5&#x02013;9<break/>(<italic>n</italic>&#x02009;=&#x02009;290)</th><th align="left" colspan="2">Clinical Symptoms<break/>PHQ-9&#x02009;&#x02265;&#x02009;10<break/>(<italic>n</italic>&#x02009;=&#x02009;119)</th></tr><tr><th align="left">m (<italic>SD</italic>)</th><th align="left">n (%)</th><th align="left">m (<italic>SD</italic>)</th><th align="left">n (%)</th><th align="left">m (<italic>SD</italic>)</th><th align="left">n (%)</th><th align="left">m (<italic>SD</italic>)</th><th align="left">n (%)</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left">68.4 (6.4)</td><td align="left"/><td align="left">68.7 (6.5)</td><td align="left"/><td align="left">68.4 (6.9)</td><td align="left"/><td align="left">66.5 (6.0)</td><td align="left"/></tr><tr><td align="left">Sex (female)</td><td align="left"/><td align="left">612 (55.1)</td><td align="left"/><td align="left">322 (45.9)</td><td align="left"/><td align="left">201 (69.3)</td><td align="left"/><td align="left">89 (74.8)</td></tr><tr><td align="left">MCI (MoCA&#x02009;&#x02264;&#x02009;24)</td><td align="left"/><td align="left">382 (34.4)</td><td align="left"/><td align="left">242 (34.5)</td><td align="left"/><td align="left">94 (32.4)</td><td align="left"/><td align="left">46 (38.7)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: m, mean; SD, standard deviation; %, frequency of the reference group (in brackets) for the respective category; PHQ-9, Patient Health Questionnaire-9, range 0&#x02013;27; MoCA, Montreal Cognitive Assessment, range 0&#x02013;30, scores&#x02009;&#x02264;&#x02009;24 indicate Mild Cognitive Impairment</p></table-wrap-foot></table-wrap>
</p><p id="Par23">Kruskal-Wallis tests were performed to investigate possible differences in MoCA subscores between individuals with no, mild, or noticeable symptoms of a depressive episode. No significant differences were found in visuospatial functioning (<italic>H</italic>(2)&#x02009;=&#x02009;0.053, <italic>p</italic>&#x02009;=.974), executive functioning (<italic>H</italic>(2)&#x02009;=&#x02009;0.331, <italic>p</italic>&#x02009;=.848), attention (<italic>H</italic>(2)&#x02009;=&#x02009;0.518, <italic>p</italic>&#x02009;=.772), speech (<italic>H</italic>(2)&#x02009;=&#x02009;4.691, <italic>p</italic>&#x02009;=.096), memory (<italic>H</italic>(2)&#x02009;=&#x02009;0.466, <italic>p</italic>&#x02009;=.792), orientation (<italic>H</italic>(2)&#x02009;=&#x02009;0.076, <italic>p</italic>&#x02009;=.963), or the MoCA total score (<italic>H</italic>(2)&#x02009;=&#x02009;1.196, <italic>p</italic>&#x02009;=.550) across the different depression categories.</p><p id="Par24">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>MoCA subscores</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">MoCA&#x02013; subscores<break/>(max. score)</th><th align="left">Total Sample<break/>(<italic>N</italic>&#x02009;=&#x02009;1,111)</th><th align="left">No Symptoms<break/>PHQ-9&#x02009;=&#x02009;0&#x02013;4<break/>(<italic>n</italic>&#x02009;=&#x02009;702)</th><th align="left">Subclinical Symptoms<break/>PHQ-9&#x02009;=&#x02009;5&#x02013;9<break/>(<italic>n</italic>&#x02009;=&#x02009;290)</th><th align="left">Clinical Symptoms<break/>PHQ-9&#x02009;&#x02265;&#x02009;10<break/>(<italic>n</italic>&#x02009;=&#x02009;119)</th></tr><tr><th align="left">m (<italic>SD</italic>)</th><th align="left">m (<italic>SD</italic>)</th><th align="left">m (<italic>SD</italic>)</th><th align="left">m (<italic>SD</italic>)</th></tr></thead><tbody><tr><td align="left">Visuospatial (4)</td><td align="left">3.29 (0.80)</td><td align="left">3.27 (0.03)</td><td align="left">3.33 (0.40)</td><td align="left">3.29 (0.29)</td></tr><tr><td align="left">Executive (4)</td><td align="left">2.57 (0.90)</td><td align="left">2.58 (0.03)</td><td align="left">2.57 (0.05)</td><td align="left">2.50 (0.09)</td></tr><tr><td align="left">Attention (6)</td><td align="left">5.34 (0.84)</td><td align="left">5.36 (0.03)</td><td align="left">5.32 (0.05)</td><td align="left">5.30 (0.08)</td></tr><tr><td align="left">Memory (5)</td><td align="left">3.29 (1.47)</td><td align="left">3.28 (0.06)</td><td align="left">3.33 (0.09)</td><td align="left">3.24 (0.14)</td></tr><tr><td align="left">Language (5)</td><td align="left">4.75 (0.54)</td><td align="left">4.76 (0.02)</td><td align="left">4.75 (0.03)</td><td align="left">4.64 (0.06)</td></tr><tr><td align="left">Orientation (6)</td><td align="left">5.80 (0.49)</td><td align="left">5.79 (0.02)</td><td align="left">5.81 (0.03)</td><td align="left">5.81 (0.04)</td></tr><tr><td align="left">Total Score (30)</td><td align="left">25.03 (2.73)</td><td align="left">25.04 (0.11)</td><td align="left">25.12 (0.15)</td><td align="left">24.78 (0.27)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: m, mean; SD, standard deviation; PHQ-9, Patient Health Questionnaire-9, range 0&#x02013;27; MoCA, Montreal Cognitive Assessment, range 0&#x02013;30, scores&#x02009;&#x02264;&#x02009;24 indicate Mild Cognitive Impairment</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Sensitivity analysis</title><p id="Par25">The mean age of people with psychometrically defined MCI (MoCA total score&#x02009;&#x02264;&#x02009;24; <italic>n</italic>&#x02009;=&#x02009;333) was 70.9 years (SD&#x02009;=&#x02009;7.09), and 51.7% were female. The MoCA total score and each MoCA subscore for people with no symptoms (68.2%), subclinical symptoms (26.3%), and clinical symptoms (5.7%) of depression as well as the results of the Kruskal-Wallis test can be found in Supplement <xref rid="MOESM1" ref-type="media">1</xref>. No significant differences were found in MoCA scores across the depression categories. Likewise, no significant differences were found when applying the original MoCA item structure. Item scores and results of the Kruskal-Wallis test can be found in Supplement <xref rid="MOESM1" ref-type="media">2</xref>.</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par26">The aim of this paper was to compare performance on the MoCA total score and subscores for people with no symptoms, subclinical symptoms, and clinical symptoms of depression.</p><p id="Par27">This sample is comparable to other studies or prevalence rates in the population with respect to the frequency of depressive symptoms: In the present sample, the rate of depressive symptoms was higher in women than in men, in line with the review results of Eid et al. [<xref ref-type="bibr" rid="CR35">35</xref>]. The gender ratio of 3:1 that was found in the German sample in the present study corresponds to the gender ratio in other high-income countries reported by Bormet et al. [<xref ref-type="bibr" rid="CR36">36</xref>] as well as to the ratio found in a more diverse sample of older people reported in Padayachey et al. [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par28">In contrast to previous studies using the MoCA [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] or other cognitive tests [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], no differences in performance could be found between people with and without depressive symptoms. Both Dierckx et al. [<xref ref-type="bibr" rid="CR20">20</xref>] and Blair et al. [<xref ref-type="bibr" rid="CR17">17</xref>] reported lower scores on participants&#x02019; overall test performance, especially on the visuospatial and executive tasks, for people with symptoms of depression compared with people without symptoms of depression. In the current study, no group differences were found in either the visuospatial or executive subscores. As neither previous study used subscores but instead compared performance on each MoCA item separately via t-tests, it could be assumed that differences in task performance may have remained undetected in the current study because subscores were analyzed. However, removing the categorization of the MoCA subscores in the second sensitivity analysis showed that focusing on the individual items did not change the results. Thus, the considerably smaller sample sizes in Dierckx et al. [<xref ref-type="bibr" rid="CR20">20</xref>] and Blair et al. [<xref ref-type="bibr" rid="CR17">17</xref>] may offer an alternative explanation for the differences that were found in their work but could not be found in the current study.</p><p id="Par29">However, it should be emphasized that negative screening results for MCI in the MoCA do not necessarily indicate normal cognitive performance. Additionally, finding no differences in cognitive performance between people with no symptoms, subclinical symptoms, and clinical symptoms of depression does not imply that cognitive impairment in people with depression does not exist. Lee et al. [<xref ref-type="bibr" rid="CR21">21</xref>] reported differences in cognitive performance between people with MCI and depression compared with people with MCI without depression in a sample with more than 3,000 participants. As they did not include participants who showed age- and education-appropriate cognitive performance, the findings from their study were limited to people who were already cognitively impaired. However, as seen in the sensitivity analysis in the present study, still no differences in test performance were found when using data only from people with MCI. It should be noted that most of the tests used in the study by Lee et al. [<xref ref-type="bibr" rid="CR21">21</xref>] were part of neuropsychological test batteries that were designed to thoroughly test for cognitive impairment. These tests may therefore be more complex than the MoCA screening test and could be more sensitive for capturing cognitive deficits in people with depression. Wei et al. [<xref ref-type="bibr" rid="CR16">16</xref>] also found that participants aged 60 and older with higher scores on the PHQ-9 had poorer performances in memory, language, and executive functioning. For the memory task, the Delayed Word Recall Test from the Consortium to Establish a Registry for Alzheimer&#x02019;s Disease was used. For this task, the participants were asked to memorize 10 words (instead of five on the MoCA) and repeat them three times (instead of once on the MoCA). Additionally, executive functioning was measured with the Digit Symbol exercise from the Wechsler Adult Intelligence Scale&#x02013; revised version, which considers psychomotor speed and learning [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par30">In a meta-analysis, Semkovska et al. [<xref ref-type="bibr" rid="CR39">39</xref>] found that, on tasks without time limits, no differences between people with depression and healthy controls could be found. As most of the tasks on the MoCA do not have time limits, factors such as psychomotor speed or processing speed are not part of the assessment [<xref ref-type="bibr" rid="CR40">40</xref>]. To fully assess cognitive impairment in people with depression, it seems that more demanding neuropsychological instruments need to be used [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par31">This study showed that in the present sample, no differences in cognitive performance were found for people with no, subclinical, and clinical depressive symptoms as measured with the German MoCA. As the MoCA is used to screen for people with MCI, people with depressive symptoms might not necessarily be challenged by the MoCA items. Therefore, according to the findings of this secondary analysis, the MoCA can be used to screen for MCI for patients with depression.</p><sec id="Sec11"><title>Limitations and strengths</title><p id="Par32">This analysis has some limitations: First, the analysis was conducted as a secondary data analysis. Thus, it was limited by the context in which the sample was collected: Interested individuals were screened for MCI to recruit participants for the BrainFit-Nutrition intervention study. No information was collected on depressive episodes or clinical diagnoses of depressive disorders. Furthermore, depressive symptoms were measured via self-assessment, which could be influenced by response biases, such as social desirability. Second, cognitive performance was assessed only with screening instruments, and MCI was not clinically diagnosed. Third, data on education was not obtained during the screening process. Therefore, MoCA scores could not be corrected for level of education. Fourth, the digital setting has a limiting effect, as only people who were willing to be examined remotely via video conference took part in the screening process.</p><p id="Par33">Nevertheless, there are also some strengths. First, the data are remarkably complete, as the participants were not able to skip questions because they were individually interviewed during the video consultation. Second, the data were collected from all over Germany to balance regional differences. Third, we used a validated screening instrument, the MoCA, to screen for MCI. The MoCA is widely used, thereby increasing comparability to other studies. Fourth, people with subclinical symptoms of depression were also included in the analysis. Fifth, an in-depth analysis of assumptions was conducted to obtain reliable results.</p></sec><sec id="Sec13"><title>Conclusions and future directions</title><p id="Par34">In conclusion, people with depression can be screened for MCI with the MoCA without its score being significantly influenced by depressive symptoms. As these findings are based on a secondary analysis, prospective studies should be planned that can provide further evidence. For these future studies, more data from people with clinical signs of depression should be collected. Additionally, the use of several instruments to assess cognitive performance might be helpful to explain possible intra- and inter-individual differences or similarities in test performance.</p></sec></sec><sec id="Sec14" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12877_2025_6004_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank all the study participants for their willingness to take part in the study. Special thanks go to Karl and Veronica Carstens Stiftung, whose support made the study possible. We also thank our English language editor, Dr. Jane Zagorski. Furthermore, we like to thank our student assistant Hannah Sch&#x000e4;del for her important contribution to this paper.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, SB, JSS, PS, and EG; methodology, SB and JSS; formal analysis, SB; investigation SB and JSS; data curation, SB, PS; writing&#x02014;original draft preparation, SB and JSS; writing&#x02014;review and editing, PS, EG, CK; supervision, EG; project administration, JSS, PS, and SB; funding acquisition, EG and CK. All authors have read and agreed to the published version of the manuscript. All authors read and approved the final manuscript. The present work was performed in partial fulfillment of the requirements for obtaining the degree &#x0201c;Dr. rer. biol. hum.&#x0201d; by SB.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p><p>This study was funded by the Karl and Veronica Carstens Foundation (funding number KVC0/117/2021E).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data presented in this study are available upon reasonable request from the corresponding author. The data are not publicly available due to privacy.</p></notes><notes><title>Declarations</title><notes id="FPar4"><title>Ethics approval and consent to participate</title><p id="Par35">All studies in humans described herein were conducted with the approval of the responsible ethics committee, in accordance with national law and the Declaration of Helsinki of 1975 (in the current revised version). Informed consent was obtained from all participants. Approval for the study and the manner in which consent was obtained was granted by the Ethics Committee of the Medical Faculty of the University of Erlangen (Registration Number 21&#x02013;318_1-B).</p></notes><notes id="FPar9"><title>Informed consent</title><p id="Par36">Written informed consent to publish the results was obtained from all participants involved in the study.</p></notes><notes id="FPar5"><title>Consent for publication</title><p id="Par37">Not applicable.</p></notes><notes id="FPar6" notes-type="COI-statement"><title>Competing interests</title><p id="Par38">CK is a member of the scientific advisory board of Bruno Zimmer, Mittel zum Leben. All the other authors declare no conflict of interest.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>MANOVA</term><def><p id="Par39">Multivariate Analysis of Variance</p></def></def-item><def-item><term>MCI</term><def><p id="Par40">Mild Cognitive Impairment</p></def></def-item><def-item><term>MMSE</term><def><p id="Par41">Mini Mental Status Examination</p></def></def-item><def-item><term>MoCA</term><def><p id="Par42">Montreal Cognitive Assessment</p></def></def-item><def-item><term>PHQ-9</term><def><p id="Par43">Patient Health Questionnaire-9</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Nasreddine</surname><given-names>ZS</given-names></name><name><surname>Phillips</surname><given-names>NA</given-names></name><name><surname>Bedirian</surname><given-names>V</given-names></name><name><surname>Charbonneau</surname><given-names>S</given-names></name><name><surname>Whitehead</surname><given-names>V</given-names></name><name><surname>Collin</surname><given-names>I</given-names></name><etal/></person-group><article-title>The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment</article-title><source>J Am Geriatr Soc</source><year>2005</year><volume>53</volume><issue>4</issue><fpage>695</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53221.x</pub-id><pub-id pub-id-type="pmid">15817019</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695&#x02013;9.<pub-id pub-id-type="pmid">15817019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Breton</surname><given-names>A</given-names></name><name><surname>Casey</surname><given-names>D</given-names></name><name><surname>Arnaoutoglou</surname><given-names>NA</given-names></name></person-group><article-title>Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies</article-title><source>Int J Geriatr Psychiatr</source><year>2019</year><volume>34</volume><issue>2</issue><fpage>233</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/gps.5016</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Breton A, Casey D, Arnaoutoglou NA. Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: meta-analysis of diagnostic accuracy studies. Int J Geriatr Psychiatr. 2019;34(2):233&#x02013;42.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Kasper</surname><given-names>S</given-names></name><name><surname>Bancher</surname><given-names>C</given-names></name><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Forstl</surname><given-names>H</given-names></name><name><surname>Frolich</surname><given-names>L</given-names></name><name><surname>Hort</surname><given-names>J</given-names></name><etal/></person-group><article-title>Management of mild cognitive impairment (MCI): the need for National and international guidelines</article-title><source>World J Biol Psychiatry</source><year>2020</year><volume>21</volume><issue>8</issue><fpage>579</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1080/15622975.2019.1696473</pub-id><pub-id pub-id-type="pmid">32019392</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Kasper S, Bancher C, Eckert A, Forstl H, Frolich L, Hort J, et al. Management of mild cognitive impairment (MCI): the need for national and international guidelines. World J Biol Psychiatry. 2020;21(8):579&#x02013;94.<pub-id pub-id-type="pmid">32019392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Inui</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name></person-group><article-title>Longer-term investigation of the value of 18F-FDG-PET and magnetic resonance imaging for predicting the conversion of mild cognitive impairment to Alzheimer&#x02019;s disease: a multicenter study</article-title><source>J Alzheimer&#x02019;s Dis</source><year>2017</year><volume>60</volume><issue>3</issue><fpage>877</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.3233/JAD-170395</pub-id><pub-id pub-id-type="pmid">28922157</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Inui Y, Ito K, Kato T. Longer-term investigation of the value of 18F-FDG-PET and magnetic resonance imaging for predicting the conversion of mild cognitive impairment to Alzheimer&#x02019;s disease: a multicenter study. J Alzheimer&#x02019;s Dis. 2017;60(3):877&#x02013;87.<pub-id pub-id-type="pmid">28922157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>X-H</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>X-P</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>J-T</given-names></name></person-group><article-title>Models for predicting risk of dementia: a systematic review</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2019</year><volume>90</volume><issue>4</issue><fpage>373</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2018-318212</pub-id><pub-id pub-id-type="pmid">29954871</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Hou X-H, Feng L, Zhang C, Cao X-P, Tan L, Yu J-T. Models for predicting risk of dementia: a systematic review. J Neurol Neurosurg Psychiatry. 2019;90(4):373&#x02013;9.<pub-id pub-id-type="pmid">29954871</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>RC</given-names></name></person-group><article-title>Mild cognitive impairment as a diagnostic entity</article-title><source>J Intern Med</source><year>2004</year><volume>256</volume><issue>3</issue><fpage>183</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2004.01388.x</pub-id><pub-id pub-id-type="pmid">15324362</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183&#x02013;94.<pub-id pub-id-type="pmid">15324362</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Dautzenberg</surname><given-names>G</given-names></name><name><surname>Lijmer</surname><given-names>J</given-names></name><name><surname>Beekman</surname><given-names>A</given-names></name></person-group><article-title>Diagnostic accuracy of the Montreal cognitive assessment (MoCA) for cognitive screening in old age psychiatry: determining cutoff scores in clinical practice. Avoiding spectrum bias caused by healthy controls</article-title><source>Int J Geriatr Psychiatr</source><year>2020</year><volume>35</volume><issue>3</issue><fpage>261</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/gps.5227</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Dautzenberg G, Lijmer J, Beekman A. Diagnostic accuracy of the Montreal cognitive assessment (MoCA) for cognitive screening in old age psychiatry: determining cutoff scores in clinical practice. Avoiding spectrum bias caused by healthy controls. Int J Geriatr Psychiatr. 2020;35(3):261&#x02013;9.</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Depression and other common mental disorders: global health estimates</source><year>2017</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation><mixed-citation id="mc-CR8" publication-type="book">WHO. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017.</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Zenebe</surname><given-names>Y</given-names></name><name><surname>Akele</surname><given-names>B</given-names></name><name><surname>Necho</surname><given-names>M</given-names></name></person-group><article-title>Prevalence and determinants of depression among old age: a systematic review and meta-analysis</article-title><source>Ann Gen Psychiatry</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1186/s12991-021-00375-x</pub-id><pub-id pub-id-type="pmid">33397417</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zenebe Y, Akele B, Necho M. Prevalence and determinants of depression among old age: a systematic review and meta-analysis. Ann Gen Psychiatry. 2021;20(1):1&#x02013;19.<pub-id pub-id-type="pmid">33397417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">APA. Diagnostic and statistical manual of mental disorders. 5 ed. American Psychiatric Association; 2014.</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Tetsuka</surname><given-names>S</given-names></name></person-group><article-title>Depression and dementia in older adults: a neuropsychological review</article-title><source>Aging Disease</source><year>2021</year><volume>12</volume><issue>8</issue><fpage>1920</fpage><pub-id pub-id-type="doi">10.14336/AD.2021.0526</pub-id><pub-id pub-id-type="pmid">34881077</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tetsuka S. Depression and dementia in older adults: a neuropsychological review. Aging Disease. 2021;12(8):1920.<pub-id pub-id-type="pmid">34881077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Steenland</surname><given-names>K</given-names></name><name><surname>Karnes</surname><given-names>C</given-names></name><name><surname>Seals</surname><given-names>R</given-names></name><name><surname>Carnevale</surname><given-names>C</given-names></name><name><surname>Hermida</surname><given-names>A</given-names></name><name><surname>Levey</surname><given-names>A</given-names></name></person-group><article-title>Late-life depression as a risk factor for mild cognitive impairment or Alzheimer&#x02019;s disease in 30 US Alzheimer&#x02019;s disease centers</article-title><source>J Alzheimer&#x02019;s Dis</source><year>2012</year><volume>31</volume><issue>2</issue><fpage>265</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.3233/JAD-2012-111922</pub-id><pub-id pub-id-type="pmid">22543846</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Steenland K, Karnes C, Seals R, Carnevale C, Hermida A, Levey A. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer&#x02019;s disease in 30 US Alzheimer&#x02019;s disease centers. J Alzheimer&#x02019;s Dis. 2012;31(2):265&#x02013;75.<pub-id pub-id-type="pmid">22543846</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Wiels</surname><given-names>W</given-names></name><name><surname>Baeken</surname><given-names>C</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name></person-group><article-title>Depressive symptoms in the elderly&#x02014;An early symptom of dementia? A systematic review</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00034</pub-id><pub-id pub-id-type="pmid">32116710</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wiels W, Baeken C, Engelborghs S. Depressive symptoms in the elderly&#x02014;an early symptom of dementia? A systematic review. Front Pharmacol. 2020;11:34.<pub-id pub-id-type="pmid">32116710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Mourao</surname><given-names>RJ</given-names></name><name><surname>Mansur</surname><given-names>G</given-names></name><name><surname>Malloy-Diniz</surname><given-names>LF</given-names></name><name><surname>Castro Costa</surname><given-names>E</given-names></name><name><surname>Diniz</surname><given-names>BS</given-names></name></person-group><article-title>Depressive symptoms increase the risk of progression to dementia in subjects with mild cognitive impairment: systematic review and meta&#x02010;analysis</article-title><source>Int J Geriatr Psychiatr</source><year>2016</year><volume>31</volume><issue>8</issue><fpage>905</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1002/gps.4406</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mourao RJ, Mansur G, Malloy-Diniz LF, Castro Costa E, Diniz BS. Depressive symptoms increase the risk of progression to dementia in subjects with mild cognitive impairment: systematic review and meta&#x02010;analysis. Int J Geriatr Psychiatr. 2016;31(8):905&#x02013;11.</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Sommerlad</surname><given-names>A</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Livingston</surname><given-names>G</given-names></name></person-group><article-title>Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis</article-title><source>Am J Psychiatry</source><year>2015</year><volume>172</volume><issue>4</issue><fpage>323</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2014.14070878</pub-id><pub-id pub-id-type="pmid">25698435</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(4):323&#x02013;34.<pub-id pub-id-type="pmid">25698435</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Ying</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Chandrasekar</surname><given-names>EK</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Late-life depression and cognitive function among older adults in the US: the National health and nutrition examination survey, 2011&#x02013;2014</article-title><source>J Psychiatr Res</source><year>2019</year><volume>111</volume><fpage>30</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2019.01.012</pub-id><pub-id pub-id-type="pmid">30660811</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wei J, Ying M, Xie L, Chandrasekar EK, Lu H, Wang T, et al. Late-life depression and cognitive function among older adults in the US: the National Health and Nutrition Examination Survey, 2011&#x02013;2014. J Psychiatr Res. 2019;111:30&#x02013;5.<pub-id pub-id-type="pmid">30660811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>M</given-names></name><name><surname>Coleman</surname><given-names>K</given-names></name><name><surname>Jesso</surname><given-names>S</given-names></name><name><surname>Jodoin</surname><given-names>VD</given-names></name><name><surname>Smolewska</surname><given-names>K</given-names></name><name><surname>Warriner</surname><given-names>E</given-names></name><etal/></person-group><article-title>Depressive symptoms negatively impact Montreal cognitive assessment performance: a memory clinic experience</article-title><source>Can J Neurol Sci</source><year>2016</year><volume>43</volume><issue>4</issue><fpage>513</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1017/cjn.2015.399</pub-id><pub-id pub-id-type="pmid">26842678</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Blair M, Coleman K, Jesso S, Jodoin VD, Smolewska K, Warriner E, et al. Depressive symptoms negatively impact Montreal cognitive assessment performance: a memory clinic experience. Can J Neurol Sci. 2016;43(4):513&#x02013;7.<pub-id pub-id-type="pmid">26842678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Invernizzi</surname><given-names>S</given-names></name><name><surname>Simoes Loureiro</surname><given-names>I</given-names></name><name><surname>Kandana Arachchige</surname><given-names>KG</given-names></name><name><surname>Lefebvre</surname><given-names>L</given-names></name></person-group><article-title>Late-life depression, cognitive impairment, and relationship with Alzheimer&#x02019;s disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2022</year><volume>50</volume><issue>5</issue><fpage>414</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1159/000519453</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Invernizzi S, Simoes Loureiro I, Kandana Arachchige KG, Lefebvre L. Late-life depression, cognitive impairment, and relationship with Alzheimer&#x02019;s disease. Dement Geriatr Cogn Disord. 2022;50(5):414&#x02013;24.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>S</given-names></name><name><surname>Frey</surname><given-names>BN</given-names></name><name><surname>Schneider</surname><given-names>MA</given-names></name><name><surname>Kapczinski</surname><given-names>F</given-names></name><name><surname>de Azevedo Cardoso</surname><given-names>T</given-names></name></person-group><article-title>Functional and cognitive impairment in the first episode of depression: A systematic review</article-title><source>Acta Psychiatr Scand</source><year>2022</year><volume>145</volume><issue>2</issue><fpage>156</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1111/acps.13385</pub-id><pub-id pub-id-type="pmid">34758106</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Varghese S, Frey BN, Schneider MA, Kapczinski F, de Azevedo Cardoso T. Functional and cognitive impairment in the first episode of depression: a systematic review. Acta Psychiatr Scand. 2022;145(2):156&#x02013;85.<pub-id pub-id-type="pmid">34758106</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Dierckx</surname><given-names>E</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Van der Mussele</surname><given-names>S</given-names></name><name><surname>Ponjaert-Kristoffersen</surname><given-names>I</given-names></name></person-group><article-title>P1-342: THE MONTREAL COGNITIVE ASSESSMENT INSTRUMENT: INFLUENCE OF DEPRESSIVE SYMPTOMS</article-title><source>Alzheimers Dement</source><year>2014</year><volume>10</volume><issue>4SPart11</issue><fpage>P437</fpage><lpage>8</lpage></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Dierckx E, Engelborghs S, De Deyn PP, Van der Mussele S, Ponjaert-Kristoffersen I. P1-342: the Montreal cognitive assessment instrument: influence of depressive symptoms. Alzheimers Dement. 2014;10(4SPart11):437&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Moon</surname><given-names>YS</given-names></name></person-group><article-title>Differential associations between depression and cognitive function in MCI and AD: a cross-sectional study</article-title><source>Int Psychogeriatr</source><year>2019</year><volume>31</volume><issue>8</issue><fpage>1151</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1017/S1041610218001527</pub-id><pub-id pub-id-type="pmid">30696505</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lee CH, Kim DH, Moon YS. Differential associations between depression and cognitive function in MCI and AD: a cross-sectional study. Int Psychogeriatr. 2019;31(8):1151&#x02013;8.<pub-id pub-id-type="pmid">30696505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>MM</given-names></name><name><surname>Insel</surname><given-names>PS</given-names></name><name><surname>Nelson</surname><given-names>C</given-names></name><name><surname>Tosun</surname><given-names>D</given-names></name><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Mueller</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Cortical atrophy is associated with accelerated cognitive decline in mild cognitive impairment with subsyndromal depression</article-title><source>Am J Geriatr Psychiatry</source><year>2017</year><volume>25</volume><issue>9</issue><fpage>980</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.jagp.2017.04.011</pub-id><pub-id pub-id-type="pmid">28629965</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Gonzales MM, Insel PS, Nelson C, Tosun D, Mattsson N, Mueller SG, et al. Cortical atrophy is associated with accelerated cognitive decline in mild cognitive impairment with subsyndromal depression. Am J Geriatr Psychiatry. 2017;25(9):980&#x02013;91.<pub-id pub-id-type="pmid">28629965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Scheerbaum</surname><given-names>P</given-names></name><name><surname>Book</surname><given-names>S</given-names></name><name><surname>Jank</surname><given-names>M</given-names></name><name><surname>Hanslian</surname><given-names>E</given-names></name><name><surname>DellO&#x02019;ro</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><etal/></person-group><article-title>Computerised cognitive training tools and online nutritional group counselling for people with mild cognitive impairment: study protocol of a completely digital, randomised, controlled trial</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><issue>7</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1136/bmjopen-2021-060473</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Scheerbaum P, Book S, Jank M, Hanslian E, DellO&#x02019;ro M, Schneider J, et al. Computerised cognitive training tools and online nutritional group counselling for people with mild cognitive impairment: study protocol of a completely digital, randomised, controlled trial. BMJ Open. 2022;12(7):1&#x02013;13.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Kassen&#x000e4;rztliche Bundesvereinigung (KBV). List of certified video service providers. Version: 30 April 2025. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.kbv.de/media/sp/liste_zertifizierte-Videodienstanbieter.pdf">https://www.kbv.de/media/sp/liste_zertifizierte-Videodienstanbieter.pdf</ext-link></mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Kroenke</surname><given-names>K</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>JBW</given-names></name></person-group><article-title>The PHQ-9: validity of a brief depression severity measure</article-title><source>J Gen Intern Med</source><year>2001</year><volume>16</volume><issue>9</issue><fpage>606</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1497.2001.016009606.x</pub-id><pub-id pub-id-type="pmid">11556941</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606&#x02013;13.<pub-id pub-id-type="pmid">11556941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Caoimh</surname><given-names>R</given-names></name><name><surname>Timmons</surname><given-names>S</given-names></name><name><surname>Molloy</surname><given-names>DW</given-names></name></person-group><article-title>Screening for mild cognitive impairment: comparison of MCI specific screening instruments</article-title><source>J Alzheimer&#x02019;s Dis</source><year>2016</year><volume>51</volume><issue>2</issue><fpage>619</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3233/JAD-150881</pub-id><pub-id pub-id-type="pmid">26890758</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">O&#x02019;Caoimh R, Timmons S, Molloy DW. Screening for mild cognitive impairment: comparison of MCI specific screening instruments. J Alzheimer&#x02019;s Dis. 2016;51(2):619&#x02013;29.<pub-id pub-id-type="pmid">26890758</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Ciesielska</surname><given-names>N</given-names></name><name><surname>Sokolowski</surname><given-names>R</given-names></name><name><surname>Mazur</surname><given-names>E</given-names></name><name><surname>Podhorecka</surname><given-names>M</given-names></name><name><surname>Polak-Szabela</surname><given-names>A</given-names></name><name><surname>Kedziora-Kornatowska</surname><given-names>K</given-names></name></person-group><article-title>Is the Montreal cognitive assessment (MoCA) test better suited than the Mini-Mental state examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis</article-title><source>Psychiatr Pol</source><year>2016</year><volume>50</volume><issue>5</issue><fpage>1039</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.12740/PP/45368</pub-id><pub-id pub-id-type="pmid">27992895</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ciesielska N, Sokolowski R, Mazur E, Podhorecka M, Polak-Szabela A, Kedziora-Kornatowska K. Is the Montreal cognitive assessment (MoCA) test better suited than the mini-mental state examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol. 2016;50(5):1039&#x02013;52.<pub-id pub-id-type="pmid">27992895</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Thomann</surname><given-names>AE</given-names></name><name><surname>Berres</surname><given-names>M</given-names></name><name><surname>Goettel</surname><given-names>N</given-names></name><name><surname>Steiner</surname><given-names>LA</given-names></name><name><surname>Monsch</surname><given-names>AU</given-names></name></person-group><article-title>Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal cognitive assessment</article-title><source>Alzheimers Res Ther</source><year>2020</year><volume>12</volume><issue>1</issue><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/s13195-020-00603-8</pub-id><pub-id pub-id-type="pmid">32264975</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Thomann AE, Berres M, Goettel N, Steiner LA, Monsch AU. Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal cognitive assessment. Alzheimers Res Ther. 2020;12(1):39.<pub-id pub-id-type="pmid">32264975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Negeri ZF, Levis B, Sun Y, He C, Krishnan A, Wu Y et al. Accuracy of the Patient Health Questionnaire-9 for screening to detect major depression: updated systematic review and individual participant data meta-analysis. BMJ. 2021;375.</mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteside</surname><given-names>DM</given-names></name><name><surname>Kealey</surname><given-names>T</given-names></name><name><surname>Semla</surname><given-names>M</given-names></name><name><surname>Luu</surname><given-names>H</given-names></name><name><surname>Rice</surname><given-names>L</given-names></name><name><surname>Basso</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Verbal fluency: Language or executive function measure?</article-title><source>Appl Neuropsychol Adult</source><year>2016</year><volume>23</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1080/23279095.2015.1004574</pub-id><pub-id pub-id-type="pmid">26111011</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Whiteside DM, Kealey T, Semla M, Luu H, Rice L, Basso MR, et al. Verbal fluency: language or executive function measure? Appl Neuropsychol Adult. 2016;23(1):29&#x02013;34.<pub-id pub-id-type="pmid">26111011</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Aita SL, Beach JD, Taylor SE, Borgogna NC, Harrell MN, Hill BD. Executive, language, or both? An examination of the construct validity of verbal fluency measures. Appl Neuropsychol Adult. 2018;26(5):441&#x02013;51.</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="book"><person-group person-group-type="author"><name><surname>Julayanont</surname><given-names>P</given-names></name><name><surname>Phillips</surname><given-names>N</given-names></name><name><surname>Chertkow</surname><given-names>H</given-names></name><name><surname>Nasreddine</surname><given-names>ZS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Larner</surname><given-names>AJ</given-names></name></person-group><article-title>Montreal cognitive assessment (MoCA): concept and clinical review</article-title><source>Cognitive screening instruments A practical approach</source><year>2013</year><publisher-loc>London</publisher-loc><publisher-name>Springer</publisher-name><fpage>111</fpage><lpage>51</lpage></element-citation><mixed-citation id="mc-CR32" publication-type="book">Julayanont P, Phillips N, Chertkow H, Nasreddine ZS. Montreal cognitive assessment (MoCA): concept and clinical review. In: Larner AJ, editor. Cognitive screening instruments A practical approach. London: Springer; 2013. pp. 111&#x02013;51.</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Nasreddine ZS. Remote MoCA Testing. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://mocacognition.com/remote-moca-testing">https://mocacognition.com/remote-moca-testing</ext-link></mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="book"><person-group person-group-type="author"><name><surname>Field</surname><given-names>A</given-names></name></person-group><source>Discovering statistics using IBM SPSS statistics. 5th. Edition ed</source><year>2018</year><publisher-loc>London</publisher-loc><publisher-name>SAGE</publisher-name></element-citation><mixed-citation id="mc-CR34" publication-type="book">Field A. Discovering statistics using IBM SPSS statistics. 5th. Edition ed. London: SAGE; 2018.</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Eid</surname><given-names>RS</given-names></name><name><surname>Gobinath</surname><given-names>AR</given-names></name><name><surname>Galea</surname><given-names>LA</given-names></name></person-group><article-title>Sex differences in depression: insights from clinical and preclinical studies</article-title><source>Prog Neurobiol</source><year>2019</year><volume>176</volume><fpage>86</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2019.01.006</pub-id><pub-id pub-id-type="pmid">30721749</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Eid RS, Gobinath AR, Galea LA. Sex differences in depression: insights from clinical and preclinical studies. Prog Neurobiol. 2019;176:86&#x02013;102.<pub-id pub-id-type="pmid">30721749</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Bromet</surname><given-names>E</given-names></name><name><surname>Andrade</surname><given-names>LH</given-names></name><name><surname>Hwang</surname><given-names>I</given-names></name><name><surname>Sampson</surname><given-names>NA</given-names></name><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>de Girolamo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cross-national epidemiology of DSM-IV major depressive episode</article-title><source>BMC Med</source><year>2011</year><volume>9</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.1186/1741-7015-9-90</pub-id><pub-id pub-id-type="pmid">21791035</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.<pub-id pub-id-type="pmid">21791035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Padayachey</surname><given-names>U</given-names></name><name><surname>Ramlall</surname><given-names>S</given-names></name><name><surname>Chipps</surname><given-names>J</given-names></name></person-group><article-title>Depression in older adults: prevalence and risk factors in a primary health care sample</article-title><source>SAFP</source><year>2017</year><volume>59</volume><issue>2</issue><fpage>61</fpage><lpage>6</lpage></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Padayachey U, Ramlall S, Chipps J. Depression in older adults: prevalence and risk factors in a primary health care sample. SAFP. 2017;59(2):61&#x02013;6.</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Joy</surname><given-names>S</given-names></name><name><surname>Fein</surname><given-names>D</given-names></name><name><surname>Kaplan</surname><given-names>E</given-names></name><name><surname>Freedman</surname><given-names>M</given-names></name></person-group><article-title>Speed and memory in WAIS&#x02013;R&#x02013;NI digit symbol performance among healthy older adults</article-title><source>J Int Neuropsychol Soc</source><year>2000</year><volume>6</volume><issue>7</issue><fpage>770</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1017/S1355617700677044</pub-id><pub-id pub-id-type="pmid">11105467</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Joy S, Fein D, Kaplan E, Freedman M. Speed and memory in WAIS&#x02013;R&#x02013;NI digit symbol performance among healthy older adults. J Int Neuropsychol Soc. 2000;6(7):770&#x02013;80.<pub-id pub-id-type="pmid">11105467</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Semkovska</surname><given-names>M</given-names></name><name><surname>Quinlivan</surname><given-names>L</given-names></name><name><surname>O&#x02019;Grady</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cognitive function following a major depressive episode: a systematic review and meta-analysis</article-title><source>Lancet Psychiatry</source><year>2019</year><volume>6</volume><issue>10</issue><fpage>851</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(19)30291-3</pub-id><pub-id pub-id-type="pmid">31422920</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Semkovska M, Quinlivan L, O&#x02019;Grady T, Johnson R, Collins A, O&#x02019;Connor J, et al. Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):851&#x02013;61.<pub-id pub-id-type="pmid">31422920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Altendorff</surname><given-names>S</given-names></name><name><surname>Healy</surname><given-names>C</given-names></name><name><surname>Werring</surname><given-names>DJ</given-names></name><name><surname>Cipolotti</surname><given-names>L</given-names></name></person-group><article-title>The test accuracy of the Montreal cognitive assessment (MoCA) by stroke lateralisation</article-title><source>J Neurol Sci</source><year>2017</year><volume>373</volume><fpage>100</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2016.12.028</pub-id><pub-id pub-id-type="pmid">28131163</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Chan E, Altendorff S, Healy C, Werring DJ, Cipolotti L. The test accuracy of the Montreal cognitive assessment (MoCA) by stroke lateralisation. J Neurol Sci. 2017;373:100&#x02013;4.<pub-id pub-id-type="pmid">28131163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>M</given-names></name><name><surname>Mahon</surname><given-names>K</given-names></name><name><surname>Burdick</surname><given-names>KE</given-names></name></person-group><article-title>Measuring cognitive function in MDD: emerging assessment tools</article-title><source>Depress Anxiety</source><year>2015</year><volume>32</volume><issue>4</issue><fpage>262</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/da.22297</pub-id><pub-id pub-id-type="pmid">25421437</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Russo M, Mahon K, Burdick KE. Measuring cognitive function in MDD: emerging assessment tools. Depress Anxiety. 2015;32(4):262&#x02013;9.<pub-id pub-id-type="pmid">25421437</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Wunner</surname><given-names>C</given-names></name><name><surname>Schubert</surname><given-names>A</given-names></name><name><surname>Gosch</surname><given-names>M</given-names></name><name><surname>Stemmler</surname><given-names>M</given-names></name></person-group><article-title>Differential diagnosis of MCI, dementia and Depression&#x02014;A comparison of different cognitive profiles</article-title><source>Psych</source><year>2022</year><volume>4</volume><issue>2</issue><fpage>187</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.3390/psych4020016</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Wunner C, Schubert A, Gosch M, Stemmler M. Differential diagnosis of MCI, dementia and depression&#x02014;A comparison of different cognitive profiles. Psych. 2022;4(2):187&#x02013;99.</mixed-citation></citation-alternatives></ref></ref-list></back></article>